A phase 1/2, open-label, multicenter study to investigate the safety, pharmacokinetics, and efficacy of fadraciclib (CYC065), an oral CDK2/9 inhibitor, in subjects with advanced solid tumors and lymphoma. (October 2022) - Piha-Paul, S.; Oh, D.Y.; Garralda, E.; Vieito, M.; Huang, J.; Kirschbaum, M.; Villanona-Calero, M.